PubMed Health⌕ Search

Biomedical subjects

M S Heilman

Publications and source records attributed to M S Heilman.

11 recordsLinked to original sources
PubMed1998

Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation.

The findings of our initial study demonstrate for the first time the ability to terminate induced VT/VF reliably (100% of all episodes) by a single, monophasic 230-J shock delivered by the Wearable Cardioverter-Defibrillator (WCD). Although limited by sample size, our data suggest the WCD could be used as a feasible bridge to definitive implantation of an implantable cardioverter-defibrillator in patients in whom risk stratification for sudden death is not completed.

Aged↗
PubMed1983

The effects of cardiovascular drugs on the defibrillation threshold and the pathological effects on the heart using an automatic implantable defibrillator.

Internal defibrillating leads were implanted in 6 dogs through a left thoracotomy and in 6 pigs through a subxiphoid approach. The effects of digoxin (0.04 mg per kilogram of body weight), procainamide (15 mg per kilogram), and propranolol (0.2 mg per kilogram) on the defibrillation threshold was determined 30 to 60 minutes following intravenous administration. Resultant blood levels were equal to or greater than therapeutic levels. Individually these drugs resulted in no appreciable change in the defibrillation threshold from baseline. Pathological study of the myocardium obtained from 6 dogs that underwent more than two hundred shocks each did not demonstrate any abnormality. The 6 pigs were reliably defibrillated, this indicating that thoracotomy is not required for successful implantation. The automatic implantable defibrillator is not the definitive treatment for recurrent ventricular arrhythmias, but is a practical regimen of therapy for a select group of high-risk, out-of-hospital patients. These observations advance our knowledge of the use of this device and give more assurance for future implantation in this select group of patients.

Animals↗
PubMed1981

Lead systems for internal ventricular fibrillation.

We examined the feasibility of using a standby automatic implantable defibrillator and established thresholds for internal defibrillation. The implantable defibrillator senses ventricular fibrillation and delivers an electrical impulse for defibrillation. Two lead systems for the device have been investigated. System I consists of two 12-cm2 silicone-covered titanium mesh patches attached to the atrial and diaphragmatic pericardial surfaces. System II has an identical diaphragmatic patch and a titanium spring catheter, with a 12-cm2 surface area of conductivity, placed transvenously in the right atrium. Both systems were implanted by thoracotomy in 12 dogs (mean weight 20 kg) and by a subxiphoid approach in 10 pigs (mean weight 20 kg). The defibrillation threshold (lowest energy required for 80% success) was determined periodically for 54 weeks in the dogs (615 trials) and at 6 weeks for the pigs (100 trials). In dogs, the mean defibrillation threshold with system I leads at 4 weeks was 10.5 J and did not change significantly over a 54-week period (p greater than 0.05). Similar results were obtained in the pig at 4 weeks. The defibrillation thresholds for both lead systems in dogs and pigs using a transpleural thoracotomy or a subxiphoid approach are satisfactory for an implantable defibrillator that produces 20-35 J.

Animals↗
PubMed1978

A chronically implanted system for automatic defibrillation in active conscious dogs. Experimental model for treatment of sudden death from ventricular fibrillation.

Ventricular defibrillation was acheived in active conscious dogs with a chronically implanted automatic system composed of a defibrillator and an alternating current fibrillator. The hermetically sealed defibrillator is encased in titanium, weighs 250 g and has a volume of 145 ml. The sensor continuously monitors ventricular electircal activity and recognizes fibrillation by the absence of isoelectric potential segments. Fibrillation is induced by placing a magnet over the implanted fibrillator. The resulting syncope closely resembles the clinical entity of sudden death, while the defibrillator automatically restores normal rhythm with a truncated exponential pulse of 30 J, 15 seconds after the onset of the arrhythmia. The operational status of the defibrillator can be tested in vitro and noninvasively in vivo with an external analyzer. This experimental model allows for the first time a long-term study of the automatic implantable defibrillator approach to prevent sudden death from ventricular fibrillation under a variety of physiopathologic conditions.

Animals↗
PubMedDate not supplied

Engineering considerations in the development of the automatic implantable cardioverter defibrillator.

Each of the authors played a significant role in the design and development of one or more of the Medrad/Intec/Cardiac Pacemakers Inc defibrillators. In so doing, each has contributed to the realization of Dr Mirowski's dream. That tens of thousands of patients have now benefitted from his leadership and that many AICDs will soon be competing in the marketplace is testimony to his truly remarkable vision and persistence.

Animals↗
PubMedDate not supplied

Considerations in the development of the automatic implantable defibrillator.

A highly reliable ventricular fibrillation detector and a satisfactory electrode system for delivering defibrillating pulses to the heart play a central role in the development of an automatic implantable defibrillator suitable for clinical use. Among the four implanted electrode designs tested, the combination of an electrode placed in the superior vena cava with a conformal electrode on the apex of the heart provided satisfactory defibrillation thresholds with ease of implantation. A new sensing method is also described for which an electrogram derived from the defibrillating electrodes is used as input. A form of a density function is developed for a filtered version of the input, ventricular fibrillation being characterized by a density curve lacking a large peak occurring at a level corresponding to the baseline of the filtered signal. These ideas are being incorporated into the design of a prototype implantable defibrillator delivering pulses of 24 joules.

Animals↗